" class="no-js "lang="en-US"> Immunologix Laboratories Appoints Dr. Corinna Fiorotti As Chief Commercial Officer (CCO) - Medtech Alert
Thursday, June 20, 2024

Immunologix Laboratories Appoints Dr. Corinna Fiorotti As Chief Commercial Officer (CCO)

Immunologix Laboratories announced today that Dr. Corinna Fiorotti has been appointed Chief Commercial Officer. An experienced science and business leader, Dr. Fiorotti assumed responsibilities on August 1, 2022 and will oversee all aspects of Immunologix Laboratories commercial function, including business development, marketing, and commercial growth

“We are fortunate to have someone of Dr. Fiorotti’s caliber and experience step up to lead the commercial operation, including the business development team, at Immunologix” said Michael Anderson, President and CEO. “Corinna is strategically positioned for the role of CCO as she has a deep understanding of our business from both the scientific and business points of view and brings a strong track record of business success. As a member of our unique Translational Sciences team at Immunologix for the past 2 years, Dr. Fiorotti has built an in-depth understanding of our services and the market. She is a strong communicator who is customer focused and possesses operational and leadership capabilities to successfully execute on the company’s strategy and growth plans”

Dr. Fiorotti holds a Ph.D. in Microbiology and Immunology and has worked in drug development for 19 years, with combined experience from both Sponsor and CRO organizations. She therefore brings a comprehensive perspective to the business development endeavors at Immunologix and is uniquely positioned to serve as CCO.

Fiorotti said, “I am honored and excited to lead the commercial team at Immunologix Laboratories. It is a privilege to be part of an organization that delivers such high caliber bioanalytical and biomarker services and innovative scientific solutions to our clients to help them bring lifesaving therapies to patients. Immunologix has an exceptional scientific team that is truly passionate about the work we do.  Our culture is built around a commitment to high quality science for our clients and providing scientific growth opportunities for our staff. We are an organization led by purpose, to make a positive, meaningful impact on the client projects that we support and thereby to improving the lives of patients.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more